UBS Group set a €110.00 ($127.91) price target on Bayer (FRA:BAYN) in a report published on Thursday, March 28th, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts also recently weighed in on the stock. Barclays set a €90.00 ($104.65) target price on shares of Bayer and gave the company a buy rating in a research note on Wednesday, November 28th. Goldman Sachs Group set a €78.00 ($90.70) price target on shares of Bayer and gave the stock a buy rating in a report on Thursday, November 29th. JPMorgan Chase & Co. restated a buy rating on shares of Bayer in a report on Thursday, November 29th. Sanford C. Bernstein set a €88.00 ($102.33) price target on shares of Bayer and gave the stock a buy rating in a report on Thursday, November 29th. Finally, Independent Research set a €69.00 ($80.23) price target on shares of Bayer and gave the stock a neutral rating in a report on Friday, November 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. Bayer currently has a consensus rating of Hold and an average price target of €81.80 ($95.12).
Bayer stock traded down €0.38 ($0.44) during mid-day trading on Thursday, reaching €61.16 ($71.12). 4,465,525 shares of the company’s stock traded hands. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Portfolio Manager
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.